Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Phase II company
Press releases
-
Response letter to previous article published about Alzstatin’s unique mode of action against Alzheimer’s
October 14, 2025
-
AlzeCure Pharma to present at Redeye Neurology Day on October 15
October 7, 2025
-
Positive study results with TrkA-NAM ACD137 against knee osteoarthritis presented at pain conference NeuPSIG 2025
September 8, 2025